Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis

2018 ◽  
Vol 2 ◽  
pp. S80
Author(s):  
A Teeple ◽  
E Muser
Keyword(s):  
Clinical Trials ◽  
Plaque Psoriasis ◽  
Certolizumab Pegol ◽  
Severe Plaque Psoriasis ◽  
Responder Analysis ◽  
Cost Per Responder

Abstract not available. Disclosures: Study sponsored by Janssen. Copyright 2018 SKIN

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis

2011 ◽  
Vol 22 (3) ◽  
pp. 138-143 ◽  
Author(s):  
Silas Martin ◽  
Steven R. Feldman ◽  
Matthias Augustin ◽  
Philippe Szapary ◽  
Brad Schenkel
Keyword(s):  
Plaque Psoriasis ◽  
Severe Plaque Psoriasis ◽  
Responder Analysis ◽  
Cost Per Responder
Sign in / Sign up

Export Citation Format

Share Document